Keytruda’s outstanding performance in the KEYNOTE-522 trial has set it apart from Roche’s PD-L1 inhibitor, Tecentriq (atezolizumab). Credit: Sonis Photography via Shutterstock. At the European Society ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...